2025-11-03T10:22:39-06:00 2024-12-31 231406493 MORISON COGEN LLP 484 NORRISTOWN RD STE 100 BLUE BELL PA 19422 990 2024-01-01 232818395 NATIONAL COMPREHENSIVE CANCER NETWORK NATI 2156900300 3025 CHEMICAL ROAD 100 PLYMOUTH MEETING PA 19462 EILEEN BOSCIA CHIEF FINANCAL OFFICER 2156900300 2025-10-30 1 0 JOSEPH M KISTNER CPA P00157086 2674403000 2024 2025-03-06 01:10:19Z CRYSTAL S DENLINGER MD 3025 CHEMICAL ROAD 100 PLYMOUTH MEETING PA 19462 55716889 0 X WWW.NCCN.ORG X 1993 DE TO DEFINE AND ADVANCE QUALITY, EFFECTIVE, EQUITABLE, AND ACCESSIBLE CANCER CARE AND PREVENTION SO ALL PEOPLE CAN LIVE BETTER LIVES. 36 36 178 1959 137080 63499 19382123 18867934 27438034 27148878 3911937 4909013 3070755 4791064 53802849 55716889 2278263 2818537 0 0 25290359 27020902 0 0 701329 12343413 13673544 39912035 43512983 13890814 12203906 152900973 172948425 37302818 41904176 115598155 131044249 X TO DEFINE AND ADVANCE QUALITY, EFFECTIVE, EQUITABLE, AND ACCESSIBLE CANCER CARE AND PREVENTION SO ALL PEOPLE CAN LIVE BETTER LIVES. 0 0 20849993 24754029 NCCN GUIDELINES, NCCN CONTENT & EDUCATIONAL PROGRAMS:EXPERTS FROM MAJOR ACADEMIC CANCER CENTERS, DEVELOP AND UPDATE CLINICAL PRACTICE GUIDELINES FOR TREATMENT OF CANCER; INCLUDES BOTH DISTRIBUTION OF GUIDELINES FOR NON-COMMERCIAL USE AS WELL AS CERTAIN EDUCATIONAL CONFERENCES AND SYMPOSIA TO COMMUNICATE CONTENT FREE OF CHARGE. 5244819 1869544 PATIENT INFORMATION:DISSEMINATION OF PATIENT INFORMATION BASED ON GUIDELINES; DEVELOPMENT AND DISSEMINATION OF MEASURES TO ASSESS THE QUALITY OF CARE. 4591735 662385 OTHER PROGRAMS: DEVELOPMENT OF OTHER PUBLIC AND PROFESSIONAL INFORMATION PROGRAMS TO FACILITATE ACCESS TO CANCER SPECIALTY SERVICES. 4482814 2818537 0 DEVELOPMENT OF A CLINICAL RESEARCH NETWORK OF PHYSICIANS AT MEMBER ACADEMIC CANCER CENTERS TO FACILITATE THE CONDUCT OF STUDIES TO ADVANCE STATE-OF-THE-ART CANCER CARE. 4482814 2818537 0 35169361 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 0 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 1 275 0 1 178 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 36 36 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT FL GA HI IL KS KY LA ME MD MA MI MS MN MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X EILEEN BOSCIA 2156900300 3025 CHEMICAL ROAD SUITE 100 PLYMOUTH MEETING PA 19462 MATT KALAYCIO MD DIRECTOR, VICE-CHAIR 2.00 X 0 0 0 PATRICK J O'BRIEN MBA DIRECTOR, TREASURER 2.00 X 0 0 0 MARIA M GONZALEZ MPH BS SECRETARY 2.00 X 0 0 0 ROBERT H VONDERHEIDE MD DPHIL DIRECTOR 2.00 X 0 0 0 RAVI SALGIA MD PHD DIRECTOR 2.00 X 0 0 0 CRAIG A BUNNELL MD MBA MPH DIRECTOR 2.00 X 0 0 0 EDWIN P ALYEA III MD DIRECTOR 2.00 X 0 0 0 JULIE M VOSE MD MBA DIRECTOR 2.00 X 0 0 0 NANCY E DAVIDSON MD DIRECTOR 2.00 X 0 0 0 PHILIPPE E SPIESS MD MS FACS FRC DIRECTOR 2.00 X 0 0 0 TIMOTHY R DONAHUE MD DIRECTOR 2.00 X 0 0 0 DAVID G PFISTER MD DIRECTOR 2.00 X 0 0 0 LISLE M NABELL MD DIRECTOR 2.00 X 0 0 0 AL B BENSON III MD FACP FASCO DIRECTOR 2.00 X 0 0 0 STEPHEN B EDGE MD FACS FASCO DIRECTOR 2.00 X 0 0 0 TIMOTHY J EBERLEIN MD DIRECTOR 2.00 X 0 0 0 ALBERTO S PAPPO MD DIRECTOR 2.00 X 0 0 0 WILLIAM E CARSON III MD DIRECTOR 2.00 X 0 0 0 MITCHELL C POSNER MD FACS DIRECTOR 2.00 X 0 0 0 DAVID T COOKE MD FACS DIRECTOR 2.00 X 0 0 0 DIANE SIMEONE MD DIRECTOR 2.00 X 0 0 0 ALAN P VENOOK MD DIRECTOR 2.00 X 0 0 0 CHRISTOPHER H LIEU MD VICE CHAIR 2.00 X X 0 0 0 LAURA W GOFF MD MMHC MSCI DIRECTOR 2.00 X 0 0 0 ELIZABETH R PLIMACK MD MS DIRECTOR 2.00 X 0 0 0 SACHIN M APTE MD MBA MS DIRECTOR 2.00 X 0 0 0 KEVIN P LEE MD DIRECTOR 2.00 X 0 0 0 AMY E DEZERN MD MHS DIRECTOR 2.00 X 0 0 0 RONDEEP BRAR MD DIRECTOR 2.00 X 0 0 0 RICHARD D SCHULICK MD MBA FACS DIRECTOR 2.00 X 0 0 0 BRYAN J SCHNEIDER MD DIRECTOR 2.00 X 0 0 0 LEE G WILKE MD FACS DIRECTOR 2.00 X 0 0 0 STEVEN J FRANK MD DIRECTOR 2.00 X 0 0 0 ROBERT R MCWILLIAMS MD MSC MSHA DIRECTOR 2.00 X 0 0 0 CARLOS L ARTEAGA MD DIRECTOR 2.00 X 0 0 0 ERIC P WINER MD DIRECTOR 2.00 X 0 0 0 CRYSTAL DELINGER MD CHIEF EXECUTIVE OFFICER 40.00 2.00 X 679441 0 49335 GARY WEYHMULLER CHIEF OPERATING OFFICER 40.00 2.00 X 629399 0 65647 WUI-JIN KOH MD CHIEF MEDICAL OFFICER 40.00 X 614406 0 49335 EILEEN BOSCIA CHIEF FINANCIAL OFFICER 40.00 2.00 X 359832 0 50239 KRISTINA M GREGORY SENIOR VP, CLINICAL INFORM 40.00 X 375041 0 49285 PATRICK DELANEY EXECUTIVE DIRECTOR - NCCN FOUNDATION 4.00 40.00 X 221100 0 51646 BETH GAFFNEY VP - US & GLOBAL BUSINESS 40.00 2.00 X 282409 0 70766 JENNIFER TREDWELL SENIOR VP, MARKETING & COM 40.00 2.00 X 244843 0 61548 JOSEPH JUNOD SENIOR DIRECTOR, IT 40.00 X 214995 0 51324 EVELYN HANDEL SENIOR DIRECTOR, DRUGS & B 40.00 X 209717 0 33806 3831183 0 532931 79 0 1 0 CLINICAL CARE OPTIONS LLC 12001 SUNRISE VALLEY DRIVE SUITE 3 RESTON VA 20191 MEDICAL EDUCATION PROGRAM SERVICES 2557871 LOGICNETS INC 5335 WISCONSIN AVE NW WASHINGTON DC NJ 20015 PROFESSIONAL SERVICES 913300 MORGAN LEWIS & BOCKIUS LLP PO BOX 8500 S-6050 PHILADELPHIA PA 19178 LEGAL SERVICES 588450 MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET WARREN 225 BOSTON MA 02114 RESEARCH 573487 CVENT INC 8180 GREENBORO DRIVE SUITE 450 MCLEAN VA 22102 SOFTWARE 502770 32 4904960 13962974 18867934 LICENSE FEES 900099 10148273 10148273 PERMISSION FEES 900099 9644738 9644738 SUBSCRIPTIONS 900099 2288425 2288425 GUIDELINE DISTRIBUTION 900099 1704898 1704898 CONSULTING FEES 900099 1512533 1512533 1850011 1850011 27148878 4909013 4909013 4653984 4653984 ADVERTISING 541800 137080 137080 137080 55716889 27148878 137080 9562997 2818537 2818537 2658119 2064519 570769 22831 18129508 16375075 1244038 510395 1159011 1031894 96994 30123 3729549 3320497 312116 96936 1344715 1197231 112535 34949 623096 336977 286119 75000 18000 57000 1876508 1389452 487056 129004 86131 42873 311038 53450 257588 1450592 650303 800289 2119097 2119097 1711039 1523164 183025 4850 2769963 2769963 342398 342398 213267 96 213171 OTHER 784298 383682 399371 1245 CATERING 465207 386053 79154 HONORARIA 361965 361965 A/V 266129 240570 25559 174943 161802 13141 43512983 35169361 7642293 701329 5401460 4799279 25805800 21110805 7494359 6580046 1735443 1553906 363822 284393 1288578 1796387 4516726 3124529 1182380 1392197 97520342 119211479 12108789 16219933 152900973 172948425 2759255 3430132 21541988 21349445 13001575 17124599 37302818 41904176 X 111702981 127128042 3895174 3916207 115598155 131044249 152900973 172948425 12203906 3242188 0 X X 0 1 X 1 0 X 20946288 19295605 20368490 19382123 18867934 98860440 20946288 19295605 20368490 19382123 18867934 98860440 4647647 94212793 2455722 3140006 5593743 6814877 9562997 27567345 145876 174063 101795 87229 64499 573462 21973829 23520158 25922116 27438034 27148878 126003015 253004262 0.37240 0.38630 X SCHEDULE A - PART II SECTION B LINE 10 OTHER INCOME INCLUDES THE FOLLOWING ITEMS: LICENSE FEE REVENUE FOR LICENSING OF NCCN PRODUCTS $10,148,273 PERMISSION FEES 9,644,738 SUBSCRIPTION REVENUE FROM THE NCCN COMPENDIA, CHEMOTHERAPY ORDER TEMPLATES AND FLASH UDPATES 2,288,425 GUIDELINE DISTRIBUTION 1,704,898 CONSULTING REVENUE 1,512,533 EXHIBIT FEES FOR EXHIBITING AT NCCN EDUCATIONAL PROGRAMS 589,200 TUITION FEES FOR NCCN ACADEMY 550,385 REGISTRATION FEES FOR NCCN EDUCATIONAL PROGRAMS 378,495 TRENDS SURVEY FEES FOR NCCN TRENDS REPORTS 219,931 FELLOWSHIP GRANTS 112,000 TOTAL $27,148,878 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 34523 34523 35134838 35169361 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 12999 16163 31991 34523 95676 250000 250000 250000 250000 1000000 1500000 SCHEDULE C PART II-A, LINE 1 LOBBYING EXPENDITURES ON PART II-A, LINE 1 OF $34,523 INCLUDE STAFF TIME ASSOCIATED WITH LOBBYING ACTIVITIES INCLUDING BUT NOT LIMITED TO: THE REDUCING HEREDITARY CANCER ACT, THE INCREASING ACCESS TO LUNG CANCER SCREENING ACT, THE SCREENS FOR CANCER ACT, THE PSA SCREENING FOR HIM ACT, THE CLINICAL TRIAL MODERNIZATION ACT, IMPROVING SENIORS' TIMELY ACCESS TO CARE ACT, ISSUES OF SURVIVORSHIP CARE AND RISK REDUCING INTERVENTIONS, ISSUES PERTAINING TO DRUG SHORTAGES, AS WELL AS, MEETINGS WITH VARIOUS MEMBERS OF CONGRESS AND FEDERAL AGENCIES. AT THE STATE LEVEL, LOBBYING ACTIVITIES WERE FOCUSED AROUND THE PASSAGE OF COMPREHENSIVE BIOMARKER COVERAGE LEGISLATION IN PENNSYLVANIA. 2980043 2506213 473830 1536683 618316 918367 1392197 RIGHT OF USE ASSETS - OPERATING LEASES 16219933 16219933 LEASE LIAB. - OPERATING LEASES 1297467 LEASE LIAB. - OPER. LEASE - (LT) 15827132 17124599 58959077 3242188 3242188 55716889 0 55716889 43512983 0 43512983 0 43512983 EUROPE 0 0 PROGRAM SERVICES EDUCATIONAL PROGRAM 93911 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES CLINICAL PRACTICE GUIDELINES 70418 EAST ASIA & THE PACIFIC 0 0 PROGRAM SERVICES CLINICAL PRACTICE GUIDELINES 13560 MIDDLE EAST/NORTH AFRICA 0 0 PROGRAM SERVICES EDUCATIONAL PROGRAM 711 SOUTH AMERICA 0 0 PROGRAM SERVICES CLINICAL GUIDELINES 1000 0 0 0 0 0 0 179600 0 179600 0 0 0 0 0 0 PART I LINE: 3(F) THE METHOD USED TO ACCOUNT FOR THE ORGANIZATION'S EXPENDITURES IS THE ACCRUAL BASIS OF ACCOUNTING. THIS IS THE SAME METHOD USED IN THE ORGANIZATION'S FINANCIAL STATEMENTS. 1 ADVENTHEALTH ORLANDO 601 E ROLLINS ST SUITE 400 ORLANDO FL 32803 590724459 501(C)(3) 5375 0 RESEARCH DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BP320 BOSTON MA 02215 043320640 501(C)(3) 207500 0 RESEARCH DUKE UNIVERSITY 3100 TOWER BLVD STE 1300 DURHAM NC 27707 560532129 501(C)(3) 89957 0 RESEARCH FOX CHASE CANCER CENTER 333 COTTMAN AVENUE PHILADELPHIA PA 19111 232003072 501(C)(3) 82760 0 RESEARCH FRED HUTCHINSON CANCER RES CTR 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 26552 0 RESEARCH H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)(3) 79606 0 RESEARCH HEALTH RESEARCH INC ELM AND CARLTON STREETS BUFFALO NY 14263 141402155 501(C)(3) 261184 0 RESEARCH INSTITUTE FOR CANCER RESEARCH 604 COTTMAN AVENUE CHELTENHAM PA 19012 236296135 501(C)(3) 157871 0 RESEARCH JOHNS HOPKINS UNIVERSITY 733 N BROADWAY SUITE 117 BALTIMORE MD 21205 520595110 501(C)(3) 93518 0 RESEARCH KUMC RESEARCH INSTITUTE INC 3901 RAINBOW BLVD MAIL STOP 1039 KANSAS CITY KS 66160 481108830 501(C)(3) 37577 0 RESEARCH MASS GENERAL HOSPITAL 101 HUNTINGTON AVENUE SUITE 210 BOSTON MA 02199 042697983 501(C)(3) 573487 0 RESEARCH MAYO CLINIC 200 FIRST STREET SW ROCHESTER MN 55905 416011702 501(C)(3) 156232 0 RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131624182 501(C)(3) 40000 0 RESEARCH NORTHWESTERN UNIVERSITY HEALTH SYSTEM 750 N LAKE SHORE DRIVE 7TH FLOOR CHICAGO IL 60611 362167817 501(C)(3) 37936 0 RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA 1855 FOLSOM STREET ROOM 425 SAN FRANCISCO CA 94143 946036493 501(C)(3) 74375 0 RESEARCH ROSWELL PARK COMPREHENSIVE CANCER CENTER ELM CARLTON STREETS BUFFALO NY 14263 161552370 501(C)(3) 22218 0 RESEARCH STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 43176 0 RESEARCH THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER 1960 KENNY ROAD COLUMBUS OH 43221 316401599 501(C)(3) 160000 0 RESEARCH REGENTS OF UNIV OF CO DENVER 1800 GRANT ST 800 DENVER CO 80203 846000555 501(C)(3) 74988 0 RESEARCH THE TRUSTEES OF THE U OF PENN 801 SPRUCE ST PHILADELPHIA PA 19107 231352685 501(C)(3) 124882 0 RESEARCH UNIVERSITY HOSP CLEVELAND MC 11100E EUCLID AVENUE CLEVELAND OH 44106 341018992 501(C)(3) 54738 0 RESEARCH TRUSTEES OF INDIANA UNIVERSITY 509 E 3RD STREET BLOOMINGTON IN 474013654 356001673 501(C)(3) 74989 0 RESEARCH THE UNIVERSITY OF TEXAS 1515 HOLCOMBE AVENUE UNIT 176 HOUSTON TX 77030 746001118 501(C)(3) 11110 0 RESEARCH VANDERBILT UNIVERSITY MEDICAL CENTER DEPARTMENT OF FINANCE AT40303 ATLANTA GA 311920303 620476822 501(C)(3) 114250 0 RESEARCH UH SEIDMAN CANCER CENTER 11100 EUCLID AVE CLEVELAND OH 44106 900059117 501(C)(3) 137500 0 RESEARCH UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 501(C)(3) 76756 0 RESEARCH 26 PART I, LINE 2: NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) ENTERS INTO RESEARCH GRANT AGREEMENTS WITH INSTITUTIONS TO CONDUCT RESEARCH FOR INDIVIDUAL STUDY PROJECTS APPROVED BY NCCN'S SCIENTIFIC REVIEW COMMITTEES. THE SCOPE AND NATURE OF STUDIES TO BE PERFORMED BY GRANT RECIPIENTS ARE IN ACCORDANCE WITH THE APPROVED PROTOCOLS DEVELOPED BY THE PRINCIPAL INVESTIGATORS AND CONSISTENT WITH THE PROPOSALS SUBMITTED TO AND APPROVED BY THE NCCN SCIENTIFIC REVIEW COMMITTEES. PRINCIPAL INVESTIGATORS OR THEIR INSTITUTIONS MUST ATTEST THAT THEY WILL ABIDE BY THE TERMS OF NCCN RESEARCH AGREEMENTS AND THAT THE PRINCIPAL INVESTIGATORS HAVE NOT BEEN DEBARRED OR DISQUALIFIED UNDER ANY RELEVANT STATUTES. IF AN INSTITUTION DOES NOT COMMENCE A STUDY WITHIN THE REQUIRED TIMELINE, NCCN MAY REQUEST THE INVESTIGATOR SUBMIT A CORRECTIVE ACTION PLAN FOR NCCN'S APPROVAL OR TERMINATE THE STUDY. DURING THE TERM OF THE GRANT, INSTITUTIONS REPORT TO NCCN ON AT LEAST A QUARTERLY BASIS. REPORTS INCLUDE AN UPDATE ON THE STATUS AND PROGRESS OF THE FUNDED STUDIES INCLUDING AN ASSESSMENT OF TOTAL ENROLLMENT OR STUDY PROGRESS, ELIGIBILITY, AND ACCRUAL OF PATIENTS AS APPLICABLE. IN CONSIDERATION FOR PERFORMANCE OF THE STUDY, NCCN DISTRIBUTES GRANT MONIES TO INSTITUTIONS WHEN CERTAIN BENCHMARK MILESTONES ARE MET AND FINAL PAYMENT IS DISBURSED UPON RECEIPT OF THE FINAL BENCHMARK MILESTONE IN THE FORM OF FINAL REPORTS AND / OR MANUSCRIPTS. INSTITUTIONS THAT DO NOT ENROLL OR COMPLETE THEIR STUDIES FULLY ARE REQUIRED TO RECONCILE STUDY EXPENSES AT TERMINATION OR COMPLETION AND RETURN UNUSED FUNDS TO NCCN WHICH ARE IN TURN RETURNED TO THE GRANTOR. X X X X X X 0 0 0 0 0 0 0 0 0 CRYSTAL DELINGER MD CHIEF EXECUTIVE OFFICER 619441 0 60000 0 0 0 34500 0 14835 0 728776 0 0 0 GARY WEYHMULLER CHIEF OPERATING OFFICER 574279 0 55120 0 0 0 34500 0 31147 0 695046 0 0 0 WUI-JIN KOH MD CHIEF MEDICAL OFFICER 559139 0 55267 0 0 0 34500 0 14835 0 663741 0 0 0 KRISTINA M GREGORY SENIOR VP, CLINICAL INFORM 341241 0 33800 0 0 0 34450 0 14835 0 424326 0 0 0 EILEEN BOSCIA CHIEF FINANCIAL OFFICER 327591 0 32241 0 0 0 34500 0 15739 0 410071 0 0 0 BETH GAFFNEY VP - US & GLOBAL BUSINESS 256159 0 26250 0 0 0 26755 0 44011 0 353175 0 0 0 JENNIFER TREDWELL SENIOR VP, MARKETING & COM 222785 0 22058 0 0 0 23119 0 38429 0 306391 0 0 0 PATRICK DELANEY EXECUTIVE DIRECTOR - NCCN FOUNDATION 200467 0 20633 0 0 0 13635 0 38011 0 272746 0 0 0 JOSEPH JUNOD SENIOR DIRECTOR, IT 194995 0 20000 0 0 0 13313 0 38011 0 266319 0 0 0 EVELYN HANDEL SENIOR DIRECTOR, DRUGS & B 203627 0 6090 0 0 0 13449 0 20357 0 243523 0 0 0 FORM 990, PART I, LINE 6, VOLUNTEERS: NCCN HAD 1,959 VOLUNTEERS COMMIT APPROXIMATELY 49,705 VOLUNTEER HOURS AS PANEL MEMBERS UPDATING EACH OF THE NCCN GUIDELINES FOR CANCER TREATMENT. FORM 990, PART VI, SECTION B, LINE 11B NCCN PROVIDES A DRAFT COPY OF THE FORM 990 TO THE FINANCE COMMITTEE OF THE BOARD OF DIRECTORS FOR ITS REVIEW AND APPROVAL PRIOR TO FILING THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C NCCN REQUIRES OFFICERS, DIRECTORS, AND KEY EMPLOYEES TO ANNUALLY COMPLETE A CONFLICT OF INTEREST QUESTIONNAIRE. THIS QUESTIONNAIRE SHALL BE UPDATED AS NECESSARY TO REFLECT CHANGES DURING THE COURSE OF THE YEAR. COMPLETED QUESTIONNAIRES SHALL BE AVAILABLE FOR INSPECTION BY ANY BOARD MEMBER AND MAY BE REVIEWED BY NCCN'S LEGAL COUNSEL. SENIOR NCCN STAFF REVIEW THE CONFLICT OF INTEREST FORMS ANNUALLY, PROVIDE A REPORT TO THE EXECUTIVE COMMITTEE AND TAKE CORRECTIVE ACTION IF NEEDED. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION OF NCCN'S CHIEF EXECUTIVE OFFICER (CEO) IS REVIEWED PERIODICALLY BY AN INDEPENDENT ORGANIZATION ENGAGED BY THE CHAIRMAN OF NCCN'S BOARD OF DIRECTORS TO CONDUCT A SALARY COMPARABILITY STUDY AND SURVEY. A SALARY COMPARABILITY STUDY AND SURVEY WAS COMPLETED DURING 2024. THE INFORMATION FROM THE SURVEY CONDUCTED BY THE INDEPENDENT ORGANIZATION IS FORWARDED TO NCCN'S EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS FOR THEIR REVIEW. EACH YEAR, THE EXECUTIVE COMMITTEE OF NCCN'S BOARD OF DIRECTORS RECEIVES INFORMATION REGARDING THE CEO'S PAST SALARY HISTORY AS WELL AS THE CEO'S ACCOMPLISHMENTS. NCCN'S EXECUTIVE COMMITTEE SCHEDULES A CONFERENCE CALL TO REVIEW THIS INFORMATION AND TO DISCUSS RECOMMENDATIONS FOR THE CEO'S SALARY AND BONUS FOR THE UPCOMING YEAR. FORM 990, PART VI, SECTION B, LINE 15B THE COMPENSATION OF NCCN'S CHIEF OPERATING OFFICER (COO), CHIEF MEDICAL OFFICER, CHIEF SCIENTIFIC OFFICER, AND CHIEF FINANCIAL OFFICER (CFO) IS REVIEWED PERIODICALLY BY AN INDEPENDENT ORGANIZATION ENGAGED BY THE CEO OF NCCN. A SALARY COMPARABILITY STUDY AND SURVEY WAS COMPLETED DURING 2024. THE ORGANIZATION CONDUCTS A SALARY COMPARABILITY STUDY AND SURVEY FOR COMPARABLE POSITIONS IN SIMILAR ORGANIZATIONS. THE CEO REVIEWS THE SALARY STUDY AND SURVEY TO DETERMINE THE COMPENSATION FOR THE ABOVE KEY EMPLOYEES OF NCCN. FORM 990, PART VI, SECTION C, LINE 19 NCCN MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XII, LINE 2C: THE FINANCE COMMITTEE ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT AND SELECTION OF AN INDEPENDENT ACCOUNTANT. NCCN FOUNDATION 3025 CHEMICAL ROAD SUITE 100 PLYMOUTH MEETING PA 19462 271536314 FOUNDATION DE 501(C)(3) LINE 7 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 0 NCCN FOUNDATION L 1358875 FMV NCCN FOUNDATION O 1270761 FMV NCCN FOUNDATION P 340226 FMW PART V LINE 2(3), COLUMN C PROFESSIONAL FEES $177,550 TRAVEL AND MEETINGS 105,541 MARKETING AND PUBLIC RELATIONS 20,308 OTHER EXPENSE 19,386 OFFICE EXPENSES 15,058 SUPPLIES AND PRINTING 2,300 TELEPHONE 83 TOTAL PART V - LINE 2(3) $340,226